Skip to content

The GOALS study: evaluation of a brief cognitive-behavioural therapy (CBT) treatment to support people with psychosis to reach personal goals

The GOALS Study: a randomised controlled trial of a brief CBT intervention to promote recovery in psychosis

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ISRCTN
Registry ID
ISRCTN73188383
Enrollment
65
Registered
2013-02-20
Start date
2013-02-01
Completion date
Unknown
Last updated
2018-02-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Psychosis ? early intervention and recovery Mental and Behavioural Disorders Unspecified nonorganic psychosis

Interventions

Treatment as Usual Group: Participants in the TAU group will continue to receive all the treatment and support they currently receive, including input from their GP and psychiatrist and will be seen b

Sponsors

King's College London (UK)
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Male & Female; Upper Age Limit 65 years ; Lower Age Limit 18 years 2. Diagnosis of a Schizophrenia Spectrum Disorder or currently experiencing positive psychotic symptoms (e.g. with diagnosis of personality disorder, bipolar affective disorder or psychotic depression) 3. Accessing adult community mental health services (both early intervention or longer-term) 4. Symptoms of anxiety-related avoidance and / or depression (above clinical cut-offs) 5. Sufficient command of the English language to complete questionnaires

Exclusion criteria

Exclusion criteria: 1. Currently refusing all medication 2. Currently or recently (in last 3 months) receiving psychological therapy (CBT) 3. Primary diagnosis of an organic mental health problem 4. Primary diagnosis of substance dependency 5. Clients under the care of staff who are trained in the intervention will be excluded in order to reduce the potential for leakage of delivery of the intervention to the treatment of usual condition, should they be allocated to the control group. However, we will ensure that any eligible clients are offered access to the intervention following completion of the trial follow-up should they wish

Design outcomes

Primary

MeasureTime frame
Levels of daily activity, measured by the Time Budget Measure (Jolley et al., 2006) at the end of treatment and follow-up

Secondary

MeasureTime frame
1. Global distress (Clinical Outcomes in Routine Evaluation - Outcome Measure, Evans et al., 2000); Timepoint(s): 0, 8 and 16 weeks 2. Patient-reported outcomes (CHOICE Measure, Greenwood et al., 2010); Timepoint(s): 0, 8 and 16 weeks 3. Psychotic symptoms (Positive and Negative Syndromes Scale, Kay et al., 1987; Psychotic Rating Scal; Timepoint(s): 0, 8 and 16 weeks 4. Symptoms of anxiety and depression (Hospital Anxiety and Depression Scale, Zigmond & Snaith, 2003); Timepoint(s): 0, 8 and 16 weeks 5. Well-being (Warwick-Edinburgh Mental Well-being Scale, Tennant et al., 2007); Timepoint(s): 0, 8 and 16 weeks 6. Anxious avoidance (Mobility Inventory, Chambless et al., 1985); Timepoint(s): 0, 8 and 16 weeks

Countries

United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026